Results 101 to 110 of about 3,349,315 (392)
Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy [PDF]
, 2017 Objective: To evaluate patient perspectives regarding utilization of intravenous (IV) therapy for inflammatory arthritis (IA). Methods: This was a single-center, non-interventional, patient questionnaire-based study of adult IA patients currently ...
Black, Shawn +6 more
core +3 more sources
Dermatologic Therapy, 2020 SARS‐CoV‐2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. We aimed to assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID‐
N. Bragazzi +6 more
semanticscholar +1 more source
FEBS Letters, EarlyView.The protonated form of butyrate, as well as other short‐chain fatty acids (SCFAs), is membrane permeable. In acidic extracellular environments, this can lead to intracellular accumulation of SCFAs and cytosolic acidification. This phenomenon will be particularly relevant in acidic environments such as the large intestine or tumor microenvironments ...
Muwei Jiang +2 more
wiley +1 more source
Direct health costs of inflammatory polyarthritis 10 years after disease onset:Results from the Norfolk Arthritis Register [PDF]
, 2015 Objectives: To explore the change in direct medical costs associated with inflammatory polyarthritis (IP) 10 to 15 years after its onset. Methods: Patients from the Norfolk Arthritis Register who had previously participated in a health economic study in ...
Adam Young +13 more
core +1 more source
The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps
Ear, nose, & throat journal, 2020 Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration–approval status for CRSwNP is dupilumab.
G. Patel, Anju T Peters
semanticscholar +1 more source
A stepwise emergence of evolution in the RNA world
FEBS Letters, EarlyView.How did biological evolution emerge from chemical reactions? This perspective proposes a gradual scenario of self‐organization among RNA molecules, where catalytic feedback on random mixtures plays the central role. Short oligomers cross‐ligate, and self‐assembly enables heritable variations. An event of template‐externalization marks the transition to
Philippe Nghe
wiley +1 more source
Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia : Results From a UK National Register [PDF]
, 2017 The British Society for Rheumatology (BSR) Biologics Register in Ankylosing Spondylitis is funded by the BSR and they have receive funds for this from Pfizer, AbbVie and UCB.
Atzeni, Fabiola +8 more
core +2 more sources
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
BioDrugs, 2017 ObjectivesA systematic review was conducted to explore the immunogenicity of biologic agents across inflammatory diseases and its potential impact on efficacy/safety.MethodsLiterature searches were conducted through November 2016 to identify controlled ...
V. Strand +9 more
semanticscholar +1 more source
FEBS Letters, EarlyView.The enzyme 5‐lipoxygenase (5‐LOX) catalyzes the first step in the biosynthesis of leukotrienes (LTs) involved in inflammatory pathophysiology. After cellular stimulation, 5‐LOX translocates to the nucleus, interacting with the 5‐LOX‐activating protein (FLAP) to form LTA4 from arachidonic acid (AA).
Erik Romp +5 more
wiley +1 more source
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. [PDF]
, 2009 The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects ...
Sands, Jacob, Tuscano, Joseph M
core +2 more sources